Introduction
============

Parkinson's disease (PD) is the second most prevalent chronic neurodegenerative disorder of aging, clinically characterized by motor symptoms including resting tremor, muscle rigidity, bradykinesia, postural instability and various non-motor symptoms ([@B60]). The most evident pathological features are the progressive degeneration of dopaminergic neurons and axonal projections in the substantia nigra and the wide spreading of eosinophilic Lewy bodies whose cardinal component is α-synuclein detected in some surviving neurons ([@B25]).

The etiology underlying the development of PD remains elusive. To date, approximate 18 genes have been identified as the genetic causes for familiar PD, which have provided critical clues for the pathogenesis of the disease ([@B4]). Recently, accumulating genetic discoveries have revealed the association between vesicle trafficking and PD ([@B74]; [@B17]; [@B70]). Disruption of the cellular vesicle trafficking results in the impaired degradation of certain proteins and further leads to the abnormal protein aggregation, which exerts a toxic effect on neurons ([@B50]). Rab GTPases (Rabs) perform the basic functions in intracellular trafficking events (**Figure [1](#F1){ref-type="fig"}**). Moreover, a series of recent studies have revealed that certain Rabs are involved in the modulation of α-synuclein. Impairment of these proteins have been reported to be one of the rare causes for inherited early onset PD ([@B70]; [@B43]; [@B49]; [@B60]). These new findings provide a novel insight into the molecular pathogenesis of PD. Moreover, the pathogenic mechanisms of different PD-related genes (*SNCA*, *LRRK2*, *PINK1, Parkin* and *TMEM230*) may share a converging molecular pathway, and Rabs may serve as potential modulators in this pathway. In this review, we summarize the physiological functions of Rabs and their interactions with multiple PD-related genes (**Table [1](#T1){ref-type="table"}**).

![**Physiological functions of PD-related Rabs**. Intracellular vesicle trafficking pathways and several related Rab GTPases are presented in the above cell model. Rab1 facilitates endoplasmic reticulum (ER) to Golgi trafficking. Rab3, accompanied by Rab8, mediates the trafficking from *trans*-Golgi network (TGN) to the plasma membrane. Rab5, serving as a key factor in the early endosome formation, is required for the transport of clathrin-dependent endosomes. Rab7 mediates the fusion of late endosomes and lysosomes, which plays an important role in the autophagy-lysosome pathway. Rab8 and Rab10 facilitate trafficking of glucose transporter type 4 (GLUT4) to the plasma membrane. Rab13 regulates the junctions among epithelial cells. Rab11 and Rab35 regulate the recycling endosome trafficking. Rab7l1 plays a role in the trafficking from lysosome to TGN. Rab32 mediates the fission of mitochondria and the trafficking from TGN to melanosome.](fncel-11-00081-g001){#F1}

###### 

Parkinson's disease-related Rab GTPases.

  Rab GTPases   Localization                                    Physiological function                        Related genes                    Relevant Pathogenesis
  ------------- ----------------------------------------------- --------------------------------------------- -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rab1          ER, *cis*-Golgi, intermediate compartment       ER-Golgi                                      *SNCA*                           Rescue the toxicity induced by aberrant α-synuclein.
  Rab3          Secretory vesicles, PM                          Exocytosis, neurotransmitter release          *SNCA, LRRK2*                    Colocalize with α-synuclein and regulate its distribution. Substrate of LRRK2-mediated phosphorylation.
  Rab5          PM, CCVs, early endosome                        Endocytosis, early endosome fusion            *SNCA, LRRK2, TMEM230*           Colocalize with α-synuclein, LRRK2 and TMEM230. Together with LRRK2 regulate synaptic vesicle endocytosis.
  Rab7          Late endosome, lysosomes,                       Late endosome to lysosome                     *SNCA, LRRK2, Parkin, TMEM230*   Colocalize with α-synuclein and TMEM230. Reverse the disturbance induced by *LRRK2* defect *in vivo* and *in vitro*. Involve the *Parkin*-mediated mitophagy.
  Rab8          TGN, GLUT4-positive vesicles                    TGN-PM transport, GLUT4 trafficking           *SNCA, LRRK2, PINK1*             Interact with α-synuclein and alleviate the toxicity induced by aberrant α-synuclein. Substrate of LRRK2/PINK1-mediated phosphorylation.
  Rab10         Golgi, GLUT4-positive vesicles                  Exocytosis, TGN/RE to PM, GLUT4 trafficking   *LRRK2*                          Substrate of LRRK2 -mediated phosphorylation.
  Rab11         Golgi, recycling endosome, early endosome       TGN/RE to PM                                  *SNCA, TMEM230*                  Interact with α-synuclein and modulate its secretion. Colocalize with TMEM230.
  Rab13         Tight junctions, TGN                            Junctions among epithelial cells              *SNCA*                           Alleviate the toxicity induced by aberrant α-synuclein.
  Rab7L1        Lysosomes                                       Lysosome to TGN                               *LRRK2*                          Together with LRRK2 involve the trafficking from lysosome to TGN.
  Rab32         Mitochondria, melanosomes                       TGN to melanosome, mitochondrial fission      *LRRK2*                          Control LRRK2-related late endosomal events.
  Rab35         PM, clathrin-coated pits, recycling endosomes   RE to PM                                      *SNCA*                           Promote the aggregation and secretion of A53T α-synuclein.
  Rab39b        Golgi                                           Unknown                                       *SNCA*                           Modulate the localization of α-synuclein.

ER, endoplasmic reticulum; PM, plasma membrane; CCV, clathrin-coated vesicles; TGN, trans-Golgi network; GLUT4, Glucose transporter type 4; RE, recycling endosome

.

Rabs and their Roles in the Vesicle Trafficking Pathway
=======================================================

Rabs are the largest subfamily of Ras-like GTPases with more than 60 members in the human genome and 11 members in the yeast, serving as molecular "switches" in vesicle trafficking ([@B56]). Generally consisting of 200 amino acids, Rabs are widely distributed across the eukaryotic cells. They perform the essential functions in the formation, maturation, transport, tethering and fusion of vesicles, regulating the interactions among the major organelles and maintaining the cellular homeostasis ([@B5]). Some structural features of the primary structure contribute to the specific interactions among membranes ([@B55]; [@B44]). The GTP-binding regions are highly conserved in evolution and make Rabs present in inactive GDP-bound and active GTP-bound forms. The CAAX boxes usually contain two cysteine residues and facilitate the attachment of Rabs to the membrane after prenylation. Located upstream at CAAX boxes, the hypervariable region may enable targeting Rabs to the specific effectors. Additionally, the Rab family (RabF) motifs (RabFl∼RabF5) serve to differentiate Rabs from other members of the Ras superfamily; the Rab subfamily (RabSF) sequences play an important part in the identification of various subfamilies ([@B55]). Some studies indicate that apart from the diversity of C-terminal, RabF and RabSF are also important for the specific interactions with target effectors and membranes ([@B3]). The GTPase fold contains a six-stranded sheet and five α helices which are interconnected by 10 loops. Different forms of nucleotide-bound Rabs present distinct conformation involving the switch I and switch II regions ([@B65]). Through the cycle between active and inactive states, Rabs achieve the function as molecular "switches." The new inactive GDP-bound form interacts with Rab escort protein (REP) and is delivered to a geranylgeranyl transferase (GGTase) ([@B2]). After prenylation, the Rab GDP dissociation inhibitor (GDI) recognizes the GDP-bound Rab and regulates the specific insertion to the membrane with the assistance of a GDI dissociation factor (GDF) ([@B63]). Once the Rab interacts with the target membrane, it transforms from the GDP-bound form to the GTP-bound form, a reaction that is catalyzed by guanine nucleotide exchange factor (GEF) ([@B13]). The active GTP-bound form is recognized by the effector proteins including sorting adaptors, tethering complexes, motor proteins and various enzymes ([@B31]). Followed by hydrolysis which is stimulated by the GTPase activating protein (GAP), the trafficking event comes to an end ([@B54]).

Vesicle trafficking in the clathrin-dependent or clathrin-independent manner is the core process for the cellular membrane dynamics. Numerous Rabs are involved in the budding, uncoating, motility and fusion of vesicles via interaction with the relevant effectors. Once a Rab stimulates the association between the sorting adaptor and the distinct receptor, the cargo is shipped into a budding vesicle. Rab9, whose effector is TIP47, facilitates the interaction between TIP47 and cytoplasmic terminal of mannose-6-phosphate receptors (M6PRs) during the formation of vesicles and maintains the recycle of M6PRs from the late endosome to the trans-Golgi network (TGN) ([@B1]). Coated vesicles account for most of the membrane trafficking, and the coats are removed to allow the fusion of vesicles. The assembly polypeptide 2 (AP2) is crucial for the recruitment of clathrin, of which the μ2 subunit interacts with the cargo after phosphorylation by μ2 kinase ([@B32]). Rab5 is involved in the regulation of vesicle uncoating via either the removal of μ2 kinase or the turnover of phosphatidylinositol-4, 5-biphosphate \[PI (4, 5) P2\] ([@B59]). To validate the correct delivery of vesicles to the relevant membranes, it is necessary for Rabs to mediate vesicle trafficking along a series of motor proteins and microtubules. For example, myosin Va is linked to Rab27 by melanophilin working as an adaptor protein, and then delivers the relevant vesicles to the pericellular matrix to allow melanocytes to achieve their physiological functions ([@B71]). To ensure the specificity of membrane fusion, Rabs may cooperate with tethering factors and mediate interactions between vesicles and the relevant membrane. As a result of the overlapping binding site of endosome antigen 1 (EEA1) for Rab5 and syntaxin-6, Rabs may interact directly with SNAREs and regulate the docking and fusion with target membranes ([@B62]).

Rabs Interact with α-Synuclein and Modulate its Distribution
============================================================

α-Synuclein is a small protein encoded by *SNCA*, whose role in the pathogenesis of PD has been highly debated over the years. Initially identified as a presynaptic protein, α-synuclein may play an important role in endo- or exocytosis of synaptic vesicles ([@B29]). Recent studies revealed that α-synuclein diffused among the cells via a prion-like transmission, and the presence of extracellular α-synuclein challenged the previous notion indicating that α-synuclein was limited to the cytoplasm ([@B18]; [@B42]; [@B15]; [@B29]). As for lacking a signal sequence, part of extracellular α-synuclein has been confirmed to translocate across the membrane via the exocytosis pathway, which relies on calcium rather than the conventional manner, and the process is promoted under the stressing conditions ([@B40]; [@B33]; [@B19]). Additionally, extracellular α-synuclein can also return to the neurons via endocytosis or the clathrin-dependent manner ([@B46]; [@B41]). All of the above studies have shed new light on the role of α-synuclein in the pathogenesis of PD and indicate the possible interactions between α-synuclein and Rabs which play a critical role in modulating the vesicle trafficking.

A large number of studies have made efforts to clarify the interactions between Rabs and α-synuclein, and this field can be elucidated from two different perspectives. On the one hand, by a train of immunofluorescence, co-immunoprecipitation and other strategies, certain Rabs (Rab3a, Rab5, Rab8, Rab7, and Rab11a) have been confirmed to interact with α-synuclein in different models and protect cells from the toxicity induced by the mutation or over-expression of α-synuclein ([@B30]; [@B10]). α-Synuclein accumulation is liable to collapse endoplasmic reticulum-Golgi trafficking during the process of tethering or docking in a manner of dose and time dependence, which can be alleviated by overexpression of Ypt1/ Rab1 which helps the COPII vesicles uncoating in yeast or dopaminergic neurons ([@B11]; [@B24]). The interaction between Rab1 and α-synuclein may be mediated by prenylated Rab acceptor protein (PRA1) which serves as a GDF for Rab1 ([@B39]). Using a *Drosophila* model, [@B6] revealed that overexpression of Rab11 colocalizing with α-synuclein in intracellular inclusions could significantly reverse the synaptic potentiation at the neuromuscular junction due to the increase of synaptic vesicle size. Through a shRNA-based screen, some Rabs (Rab8b, Rab11a, and Rab13) have been identified as modulators of α-Synuclein in living cells and reduced the toxicity induced by aggregated α-synuclein via secretion enhancement ([@B27]). Rab8, playing a role in the post-Golgi trafficking, binded with the C terminal of α-synuclein, which was confirmed by the nuclear magnetic resonance spectroscopy. In cell models, Rab8 suppressed the toxicity caused by mutation or overexpression of α-synuclein ([@B73]). On the other hand, Rabs may be involved in regulating the recycling and distribution of α-synuclein, which opens a new window for new therapeutic strategies. Apart from degradation by the lysosomal pathway, the internalized extracellular α-synuclein might be partly secreted from cells via exocytosis, which might be facilitated by Rab11 ([@B45]; [@B10]). [@B10] conducted a further study that showed the co-localization of Rab11 and α-synuclein *in vivo*. In addition, they also found that Rab11 rescued the α-synuclein aggregation and cytotoxicity. However, the mechanism underlying how Rab11 regulates the secretion of α-synuclein is still disputed ([@B10]). Besides, the downregulation of the novel disease-causing gene Rab39b results in the dysregulation of α-synuclein homeostasis, which will be extensively elucidated below ([@B70]). As a protein regulating synaptic vesicles, Rab3a not only has been confirmed to have a close association with α-synuclein but also may lead to the re-distribution of α-synuclein via a conformation change ([@B7]). Recently, Rab35 was identified as a potential biomarker in the serum for the differential diagnosis and progression of PD. Besides, the functional study also suggested that overexpression of Rab35 led to increased aggregation and secretion of aberrant α-synuclein ([@B9]). Above all, these lines of evidence suggest that the α-synuclein pathology propagation may partly attribute to the dysregulation of Rabs.

The Interactions between Rabs and Different PD-Related Genes
============================================================

Leucine-Rich Repeat Kinase 2
----------------------------

Leucine-rich repeat kinase 2 (LRRK2, also known as PARK8) is a multi-domain 280 kDa protein characterized with functional GTPase and kinase domains ([@B35]). Most PD-specific mutations of *LRRK2* occur in the afore-mentioned regions and lead to autosomal recessive and several sporadic PD, which hints at the importance of these enzymes in the pathogenesis ([@B20]; [@B23]; [@B34]; [@B66]; [@B48]). LRRK2 is involved in diverse cellular molecular events, such as synaptic vesicle dynamic, mitochondrial function and autophagy ([@B57]; [@B61]; [@B68]). To support the role of *LRRK2* in vesicle trafficking, there are a few lines of evidence suggesting the complex interactions between *LRRK2* and certain Rabs.

Since the identification of the first *LRRK2*-related Rab GTPase, Rab5b, involved in synaptic vesicle endocytosis, effort has been made to investigate the novel interactive GTPases ([@B61]). Lrrk, a homolog of human LRRK2 in *Drosophila*, interacted strikingly with Rab7 and regulated the localization of lysosome ([@B16]). Besides, this study also linked the pathogenesis underlying LRRK2 G2019S to the disturbance of Rab7-mediated lysosome positioning ([@B16]). Another study also identified that the impaired trafficking from early to late endosomes induced by the mutation of *LRRK2* could be alleviated by coexpression of Rab7, which deepened the understanding of the interaction between LRRK2 and Rab7 ([@B26]). Using the transcriptomic approach, LRRK2 has been reported to bind with Rab7l1 whose polymorphism confers the reduced risk of PD at the Golgi apparatus, and the degeneration induced by G2019S could be rescued by the overexpression of the Rab7l1 in the *Drosophila* dopamine neurons ([@B21]). Furthermore, in the case of *LRRK2* mutation or *Rab7l1* knockdown, the retromer pathway components levels including VPS35 appeared reduced, which suggested that LRRK2 or Rab7l1 might be involved in the retromer pathway ([@B47]). Besides, Steger et al. used the approach of high-resolution quantitative mass spectrometry and combined it with other approaches to identify the substrates of LRRK2. However, only two sites met the strict criteria: pSer935 in LRRK2 and pThr73 of the small GTPase Rab10. In the following study, they also found the phosphorylation of some Rabs (Rab3, Rab8), which contained a Thr at the site equivalent to T73-Rab10 *in vitro* and *in vivo*. Interestingly, all of the above sites were in the switch II region which mediated the cycle of GDP/GTP for the interaction with the cellular membrane. Overexpression of *LRRK2*, to some extent, might lower the affinity of some Rabs to the GDIs and caused the abnormal insertion to the membrane and disruption of the vesicle trafficking ([@B64]). It appears that Rabs work as a downstream regulator of LRRK2 to achieve their role in vesicle trafficking. Conversely, in another study [@B69] found that Rab32 might directly interact with the amino terminal of endogenous LRRK2 and influenced LRRK2-related late endosomal events. Taken together, the physiological function of LRRK2 in vesicle trafficking is closely associated with Rabs and the dysfunction of either of the components may result in a defect in vesicle dynamics, which could ultimately lead to PD.

PTEN-Induced Kinase 1/Parkin
----------------------------

Loss-of-function mutations in the PTEN-induced kinase 1 (*PINK1*) and RBR E3 ubiquitin protein ligase (*Parkin*) usually lead to autosomal recessive PD ([@B37]; [@B67]). It has been reported that PINK1 worked as the upstream regulator of Parkin in a common pathway and was linked to the mitochondrial quality control. Once mitochondrial dysfunction is detected by PINK1, Parkin is recruited to ubiquitinate the damaged mitochondrial and clear them up via autophagy ([@B52], [@B53]; [@B75]). PD patients with *PINK1* or *Parkin* defects usually exhibit similar phenotypes. However, [@B12] observed that knockout of *Parkin* in rats did not cause so serious neurodegeneration as *PINK1*, which implicated that additional proteins might share a common pathway ([@B36]). A few investigations suggest that Rabs are candidate proteins to serve in downstream steps of the mitophagy pathway. [@B38] conducted a SILAC-based phosphoproteomic screening to identify the novel substrates of PINK1. They found that Ser111 of three Rab GTPases (Rab8a, Rab8b, and Rab13) were phosphorylated in a PINK-dependent and Parkin-independent manner. Phosphorylation of this site in Rabs might impair the interaction with the respective GEF, which thereby disrupted the activation of Rabs ([@B38]). Rab7 as well as its GAP TBC1D15 and TBC1D17 have been reported to be involved in the Parkin-mediated mitophagy. Both TBC1D15 and TBCD17 played an important role in the process of autophagosome formation and prevented the membrane from Rab7-mediated inflation ([@B72]).

Transmembrane-Protein 230
-------------------------

Transmembrane-protein 230 (*TMEM230*) gene presumably encodes a transmembrane protein with elusive physiological localization and function. The latest study by [@B14] investigating on a large North American family has revealed that TMEM230 was a disease-causing gene of PD with typical pathological features of Lewy bodies. To characterize the human TMEM230 distribution and function, a series of confocal microscopy experiments were conducted. The results showed that vesicle structures characterized with TMEM230 were predominantly located in the perinucleus region and colocalized with the markers of synaptic vesicles. Given the multiple roles of Rabs in vesicle trafficking, they also found interactions between TMEM230 and Rab5a, Rab7 or Rab11a, respectively. These findings, in turn, suggested that TMEM230 might play a role in the process of vesicle formation and trafficking; the impairment of this protein might lead to pathological features in neurons in patients with PD ([@B14]).

Rab39b
------

*Rab39b*, first isolated from the human fetal brain, encodes a neuron-specific protein with putative functions in the synapse formation and maintenance ([@B8]). Mapping to the human chromosome Xq28, loss-of-function mutations or increased dosage of *Rab39b* were confirmed to be linked to the molecular basis of X-linked mental retardation ([@B22]). To explore the mechanism underlying Rab39b-related cognitive deficits, there was evidence suggesting that Rab39b regulated the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) arrangement in the case of interaction with the PDZ domain of protein interacting with C-kinase 1 (PICK1), which was important for synaptic plasticity ([@B51]). Genetic analysis of Australian and Wisconsin kindreds first identified that the defect in *Rab39b* caused pathologically defined PD. Following functional studies revealed that altered *Rab39b* was rapidly metabolized through the proteasome pathway and might dysregulate the localization of α-synuclein ([@B70]). Based on this novel breakthrough, a large number of studies were conducted to further investigate the genetic contribution of *Rab39b* to the pathogenesis of PD ([@B43]; [@B49]; [@B28]). Recently, our team also identified a novel mutation of *Rab39b* (c.536 dup A) in a family, of which the patients displayed juvenile parkinsonism and mental retardation syndromes. Moreover, the brain magnetic resonance imaging (MRI) and computed tomography (CT) scans of both patients showed calcification in the basal ganglia, which was never reported in the previous cases ([@B60]). According to the latest study, the complex formed by C9ORF72, WDR41 and SMCR8 worked as a GEF for Rab39b as well as Rab8a, which suggested that Rab39b might be involved in the autophagy regulation ([@B58]). Albeit with constant studies focusing on the characterization of *Rab39b* molecular functions, the mechanisms of genetic defects still need to be explored.

Conclusion
==========

Over the years, many researchers have paid much attention to exploring the pathogenesis of PD to halt or slow the progression of PD and identify effective therapeutic strategies. Different hypothesizes have been proposed, such as mitochondrial dysfunction, protein misfolding and aggregation, and impaired autophagy-lysosome system. Recently, the focus has shifted to vesicle trafficking. In this review, we emphasized the importance of the functions of Rabs and their potential interplay with different PD-related genes. Rabs perform an essential role in vesicle trafficking and cellular homeostasis maintenance. Not only are Rabs closely associated with α-synuclein-mediated pathological process but they also interact with many genes whose mutations or polymorphisms lead to the development of PD. It is plausible that Rabs could be regarded as novel biomarkers or therapeutic targets before the clinical manifestation of PD. However, the role of Rabs in the molecular pathway of PD remains elusive. More functional studies should be conducted to reveal the interplay between Rabs and different effectors.
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